Skip to main content
Top
Published in: Surgery Today 11/2014

Open Access 01-11-2014 | Case Report

Pheochromocytoma as the first manifestation of MEN2A with RET mutation S891A: report of a case

Authors: Yatsuka Hibi, Tamae Ohye, Kimio Ogawa, Yoshimi Shimizu, Masahiro Shibata, Chikara Kagawa, Yutaka Mizuno, Shinya Uchino, Shinji Kosugi, Hiroki Kurahashi, Katsumi Iwase

Published in: Surgery Today | Issue 11/2014

Login to get access

Abstract

We report a rare case with pheochromocytoma as the first manifestation of multiple endocrine neoplasia type 2A with RET mutation S891A. Bilateral pheochromocytomas were identified in a 54-year-old woman. Screening for RET revealed a rare S891A mutation located in the intracellular tyrosine kinase domain. This mutation was previously recognized as one of the mutations only in cases manifesting solely medullary thyroid carcinomas (MTCs). Since calcitonin stimulation test indicated positive result, total thyroidectomy was performed 1 year after the bilateral adrenalectomy, and C-cell hyperplasia was diagnosed by histopathological examination. Our report suggests that cases with S891A mutation, akin to those with other RET mutations, require screening for pheochromocytoma. In addition, it is indicated that calcitonin stimulation test should be performed even in the unaffected elder cases with S891A mutation although the mutation is classified as lowest risk group on MTC in guidelines.
Literature
1.
go back to reference Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.PubMedCrossRef Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.PubMedCrossRef
2.
go back to reference Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–6.PubMedCrossRef Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–6.PubMedCrossRef
3.
go back to reference Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 1995;267:381–3.PubMedCrossRef Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 1995;267:381–3.PubMedCrossRef
4.
go back to reference Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.PubMedCrossRef Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.PubMedCrossRef
5.
go back to reference Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, et al. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab. 1997;82:4176–8.PubMed Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, et al. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab. 1997;82:4176–8.PubMed
6.
go back to reference Dang GT, Cote GJ, Schultz PN, Khorana S, Decker RA, Gagel RF. A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes. 1999;13:77–9.PubMedCrossRef Dang GT, Cote GJ, Schultz PN, Khorana S, Decker RA, Gagel RF. A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes. 1999;13:77–9.PubMedCrossRef
7.
go back to reference Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2005;90:3999–4003.PubMedCrossRef Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2005;90:3999–4003.PubMedCrossRef
8.
go back to reference Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, et al. Pheochromocytoma and medullary thyroid carcinoma: a new genotype–phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004;89:4142–5.PubMedCrossRef Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, et al. Pheochromocytoma and medullary thyroid carcinoma: a new genotype–phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004;89:4142–5.PubMedCrossRef
9.
go back to reference Machens A, Dralle H. Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf). 2008;69:81–7.PubMedCrossRef Machens A, Dralle H. Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf). 2008;69:81–7.PubMedCrossRef
10.
go back to reference Schulte KM, Machens A, Fugazzola L, McGregor A, Diaz-Cano S, Izatt L, et al. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. J Clin Endocrinol Metab. 2010;95:E92–7.PubMedCrossRef Schulte KM, Machens A, Fugazzola L, McGregor A, Diaz-Cano S, Izatt L, et al. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. J Clin Endocrinol Metab. 2010;95:E92–7.PubMedCrossRef
11.
go back to reference Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92:4725–9.PubMedCrossRef Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92:4725–9.PubMedCrossRef
12.
go back to reference Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype–phenotype relationship. Arch Surg. 2003;138:409–16 (discussion 416).PubMedCrossRef Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype–phenotype relationship. Arch Surg. 2003;138:409–16 (discussion 416).PubMedCrossRef
13.
go back to reference Asari R, Scheuba C, Kaczirek K, Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg. 2006;141:1199–205 (discussion 1205).PubMedCrossRef Asari R, Scheuba C, Kaczirek K, Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg. 2006;141:1199–205 (discussion 1205).PubMedCrossRef
14.
go back to reference Paszko Z, Sromek M, Czetwertynska M, Skasko E, Czapczak D, Wisniewska A, et al. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred’s from Central Poland. Cancer Invest. 2007;25:742–9.PubMedCrossRef Paszko Z, Sromek M, Czetwertynska M, Skasko E, Czapczak D, Wisniewska A, et al. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred’s from Central Poland. Cancer Invest. 2007;25:742–9.PubMedCrossRef
15.
go back to reference Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF. Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma. Rev Med Chil. 2001;129:713–8 (Spanish).PubMedCrossRef Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF. Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma. Rev Med Chil. 2001;129:713–8 (Spanish).PubMedCrossRef
16.
go back to reference Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol. 2006;155:229–36.PubMedCrossRef Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol. 2006;155:229–36.PubMedCrossRef
17.
go back to reference Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, Kikumori T, MEN Consortium of Japan, et al. High penetrance of pheochromocytoma in multiple endocrineneoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol. 2013;168:683–7.PubMedCrossRef Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, Kikumori T, MEN Consortium of Japan, et al. High penetrance of pheochromocytoma in multiple endocrineneoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol. 2013;168:683–7.PubMedCrossRef
18.
go back to reference Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612.PubMedCrossRef Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612.PubMedCrossRef
19.
go back to reference Plaza-Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, et al. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res. 2005;65:1729–37.PubMedCrossRef Plaza-Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, et al. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res. 2005;65:1729–37.PubMedCrossRef
20.
go back to reference Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene. 1999;18:3919–22.PubMedCrossRef Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene. 1999;18:3919–22.PubMedCrossRef
21.
go back to reference Cranston A, Carniti C, Martin S, Mondellini P, Hooks Y, Leyland J, et al. A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Mol Endocrinol. 2006;20:1633–43.PubMedCrossRef Cranston A, Carniti C, Martin S, Mondellini P, Hooks Y, Leyland J, et al. A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Mol Endocrinol. 2006;20:1633–43.PubMedCrossRef
22.
go back to reference Machens A, Dralle H. Genotype–phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg. 2007;31:957–68.PubMedCrossRef Machens A, Dralle H. Genotype–phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg. 2007;31:957–68.PubMedCrossRef
23.
go back to reference Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D’etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab. 1998;83:487–91.PubMed Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D’etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab. 1998;83:487–91.PubMed
Metadata
Title
Pheochromocytoma as the first manifestation of MEN2A with RET mutation S891A: report of a case
Authors
Yatsuka Hibi
Tamae Ohye
Kimio Ogawa
Yoshimi Shimizu
Masahiro Shibata
Chikara Kagawa
Yutaka Mizuno
Shinya Uchino
Shinji Kosugi
Hiroki Kurahashi
Katsumi Iwase
Publication date
01-11-2014
Publisher
Springer Japan
Published in
Surgery Today / Issue 11/2014
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-013-0826-8

Other articles of this Issue 11/2014

Surgery Today 11/2014 Go to the issue